Accession Therapeutics Limited
Jez (Andrew) Gerry has a strong background in preclinical research and development. Jez is currently working as the Chief Operating Officer and Head of Preclinical Development at Accession Therapeutics Limited since 2021. Prior to this, they held various positions at Adaptimmune, including VP of Preclinical Research, Director of Preclinical Research, Head of Pipeline Preclinical Cell Testing, Group Leader, and Senior Scientist. Jez began their career as a Postdoctoral Scientist at the University of Reading from 2004 to 2007.
Jez (Andrew) Gerry holds a Doctor of Philosophy (PhD) degree in Cell and Molecular Biology from the University of Reading. The duration of their education at this institution is not specified.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.